Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naive relapsing MS patients
Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naive relapsing MS patients
复制标题
DOI：
10.1136/jnnp-2019-321321
复制
发表时间：
2019-12-01
影响因子：
11
通讯作者：
Illes, Zsolt
中科院分区：
文献类型：
--
作者：
Sejbaek, Tobias;Nielsen, Helle Hvilsted;Illes, Zsolt
目的在一项关于一线口服治疗富马酸二甲酯（DMF）的前瞻性IV期试验中，我们检测了从复发缓解型多发性硬化（RRMS）患者中收集的12个月以上血清、血浆和脑脊液（CSF）样本中神经丝轻链（NFL）的动力学。NFL的变化与疾病activity.Methods的单分子阵列检测NFL水平在88 CSF，348血浆和131血清初治RRMS患者（n=52），健康对照组（n=23）和安慰剂组匹配的年龄，性别和NFL（n=52）。在基线和DMF后1、3、6和12个月采集血浆/血清。结果CSF、血浆和血清中NFL浓度高度相关（P
Objectives In a prospective phase IV trial of the first-line oral treatment dimethyl fumarate (DMF), we examined dynamics of neurofilament light (NFL) chain in serum, plasma and cerebrospinal fluid (CSF) samples collected over 12 months from relapsing-remitting multiple sclerosis (RRMS) patients. NFL changes were related to disease activity.Methods We examined NFL levels by single-molecule array in 88 CSF, 348 plasma and 131 sera from treatment-naive RRMS patients (n=52), healthy controls (n=23) and a placebo group matched by age, sex and NFL (n=52). Plasma/sera were collected at baseline, and 1, 3, 6 and 12 months after DMF. CSF samples were collected at baseline and 12 months after DMF.Results NFL concentration in CSF, plasma and serum correlated highly (p